<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3646">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543087</url>
  </required_header>
  <id_info>
    <org_study_id>B1971033</org_study_id>
    <secondary_id>2011-005697-31</secondary_id>
    <nct_id>NCT01543087</nct_id>
  </id_info>
  <brief_title>Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose</brief_title>
  <official_title>A PHASE 3 STUDY TO ASSESS THE PERSISTENCE OF HSBA RESPONSE UP TO 48 MONTHS AFTER COMPLETION OF A PRIMARY SERIES OF BIVALENT RLP2086, AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF BIVALENT RLP2086</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the longevity of immune response in adolescents for approximately 48&#xD;
      months after receipt of a primary series of bivalent rLP2086 vaccination, which is then&#xD;
      followed by a booster dose and an assessment of immune response for 12 or 26 months post&#xD;
      booster vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to assess the longevity of immune responses in adolescents (aged 10 to &lt;19&#xD;
      years at the time of entry into a primary study) following receipt of a vaccination regimen&#xD;
      of 2 or 3 doses of bivalent rLP2086 in a primary study. A booster dose of bivalent rLP2086 at&#xD;
      approximately 48 months was given following the final dose of the 2- or 3-dose primary&#xD;
      bivalent rLP2086 vaccination series. The study was therefore divided into Stage 1 (4-year&#xD;
      persistence of immune responses following receipt of a primary vaccination series) and the&#xD;
      booster stage (follow-up through 12 months for all boosted or 26 months for a subset of the&#xD;
      boosted).&#xD;
&#xD;
      Subjects participating only in Stage 1 will attend up to 6 study visits for collection of a&#xD;
      20-mL blood sample at each visit. Subjects participating in both Stage 1 and booster stage&#xD;
      will attend up to 9-10 study visits with 1 visit for booster dose vaccination and 8-9 visits&#xD;
      for collection of a 20-mL blood sample at each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2012</start_date>
  <completion_date type="Actual">January 5, 2018</completion_date>
  <primary_completion_date type="Actual">January 5, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 6 (Visit 1) After Primary Vaccinations</measure>
    <time_frame>Month 6 (Visit 1 of study B1971033)</time_frame>
    <description>For immunogenicity assessment, serum bactericidal assay using human complement (hSBA) was performed with 4 primary Neisseria meningitidis serogroup B (MnB) test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants who received bivalent rLP2086 in primary study B1971012, entered in this study at Month 12 (Visit 2). Hence, no participants enrolled from primary study B1971012 had serology results at Month 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 12 (Visit 2) After Primary Vaccinations</measure>
    <time_frame>Month 12 (Visit 2 of study B1971033)</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 18 (Visit 3) After Primary Vaccinations</measure>
    <time_frame>Month 18 (Visit 3 of study B1971033)</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 24 (Visit 4) After Primary Vaccinations</measure>
    <time_frame>Month 24 (Visit 4 of study B1971033)</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 36 (Visit 5) After Primary Vaccinations</measure>
    <time_frame>Month 36 (Visit 5 of study B1971033)</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 48 (Visit 6) After Primary Vaccinations</measure>
    <time_frame>Month 48 (Visit 6 of study B1971033)</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Booster Stage Participants Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 1 Month After Last Vaccination in Primary Study</measure>
    <time_frame>1 month after last vaccination in primary study</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Booster Stage Participants Achieving hSBA Titer Level (&gt;=) Lower Limit of Quantitation for Each of the 4 Primary Strains Before Booster Vaccination (48 Months After Last Vaccination in Primary Study [Visit 6])</measure>
    <time_frame>Visit 6 of study B1971033 (48 months after last vaccination in primary study)</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 1 Month After the Booster Vaccination (Visit 8)</measure>
    <time_frame>Visit 8 (1 month following the booster vaccination on Month 49)</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving hSBATiter Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 12 Months After the Booster Vaccination(Visit 10)</measure>
    <time_frame>Visit 10 (12 months following the booster vaccination on Month 60)</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving hSBA Titer Level Greater Than or Equal to(&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 26 Months After the Booster Vaccination(Visit 11)</measure>
    <time_frame>Visit 11 (26 months following the booster vaccination on Month 74)</time_frame>
    <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage. only participants who received bivalent rLP2086 in primary study B1971010 were not analysed for this endpoint. Only participants who received bivalent rLP2086 in primary study B1971012 on a 0-, 2-, and 6-month or a 0- and 6-month vaccination schedule were eligible to be followed for 26 months after booster vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Local Reactions Within 7 Days After Booster Vaccination</measure>
    <time_frame>Within 7 days after booster vaccination on Month 48</time_frame>
    <description>Local reactions were collected by using an e-diary and included pain at injection site, redness and swelling. Redness and swelling were graded as: none (0-2.0 centimetre [cm]), mild (2.5-5.0 cm), moderate (greater than [&gt;] 5.0-10.0 cm) and severe (&gt;10.0 cm). Pain was graded as: mild (does not interfere with activity), moderate (Interferes with activity) and severe (prevents daily activity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Booster Vaccination</measure>
    <time_frame>Within 7 days after booster vaccination on Month 48</time_frame>
    <description>Systemic reactions included: fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site and joint pain, all other systemic reactions were recorded by using an e-diary. Fever was categorized as: 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and &gt; 40.0 degree C. Vomiting was graded as: mild (1 to 2 times in 24 hours [hrs]), moderate (&gt;2 times in 24 hrs) and severe (requires intravenous [IV] hydration); Diarrhea was graded as: mild (2 to 3 loose stools in 24 hrs), moderate (4 to 5 loose stools in 24 hrs) and severe (6 or more loose stools in 24 hrs); Headache, fatigue, chills, muscle pain and joint pain was graded as: mild (does not interfere with daily activities), moderate (some interference with activity) and severe (prevents daily routine activity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Medically Attended Adverse Event (MAE) From Booster Vaccination Phase (Visit 7 to Visit 8)</measure>
    <time_frame>From Visit 7 (Month 48) to Visit 8 (Month 49) in Booster stage</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both non-serious AEs and serious adverse events (SAEs). An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) and Medically Attended Adverse Event (MAE) From Booster Follow-Up Phase (Visit 8 to Visit 9)</measure>
    <time_frame>Visit 8 (Month 49) to Visit 9 (Month 54) in Booster stage</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) and Medically Attended Adverse Event (MAE) From Booster Vaccination Through 6 Months After Booster Vaccination (Visit 7 to Visit 9)</measure>
    <time_frame>From Visit 7 (time of booster vaccination, Month 48) to Visit 9 (6 months after booster vaccination, Month 54)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An MAE was defined as a nonserious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Newly Diagnosed Chronic Medical Condition;(NDCMC) From the 6-Month Safety Telephone Call in the Primary Study Through 48 Months After the Last Dose in the Primary Study (Visit 6 in Stage 1)</measure>
    <time_frame>Visit 1 of B1971033 (6-month safety telephone call after last dose in primary study) to Visit 6 of B1971033 (6 months after last primary dose to 48 months after last primary dose in primary study)</time_frame>
    <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Booster Vaccination Through 12 Months After Booster Vaccination (Visit 8 to Visit 10)</measure>
    <time_frame>From Visit 8 (1 month after booster vaccination, Month 49) to Visit 10 (12 months after booster vaccination, Month 60)</time_frame>
    <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) From Booster Stage Vaccination Through 12 Months After Booster Vaccination (Visit 7 to Visit 10)</measure>
    <time_frame>From Visit 7 (time of booster vaccination, Month 48) to Visit 10 (12 months after booster vaccination, Month 60)</time_frame>
    <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Booster Vaccination Through 26 Months After Booster Vaccination (Visit 8 to Visit 11)</measure>
    <time_frame>From Visit 8 (1 month after booster vaccination, Month 49) to Visit 11 (26 months after booster vaccination, Month 74)</time_frame>
    <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC. Participants who received bivalent rLP2086 in primary study B1971012 on a 0-, 2-, and 6-month or a 0- and 6-month vaccination schedule were eligible to be follow up for 26 months after booster vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From Booster Vaccine Through 26 Months After Booster Vaccination (Visit 7 to Visit 11)</measure>
    <time_frame>From Visit 7 (time of booster vaccination, Month 48) to Visit 11 (26 months after booster vaccination, Month 74)</time_frame>
    <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC. Participants who received bivalent rLP2086 in primary study B1971012 on a 0-, 2-, and 6-month or a 0- and 6-month vaccination schedule were eligible to be follow up for 26 months after booster vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Booster Vaccination</measure>
    <time_frame>Within 30 minutes after Booster Vaccination in Month 48</time_frame>
    <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Days Participants Missed Work or School Due to AE From Booster Vaccination Through 6 Months After Booster Vaccination (Visit 7 Through Visit 9)</measure>
    <time_frame>From Visit 7 (time of booster vaccination, Month 48) Through Visit 9 (6 months after booster vaccination, Month 54)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Number of days participants missed work or school due to AE occurred following booster vaccination were reported here.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">698</enrollment>
  <condition>Meningococcal Infection</condition>
  <arm_group>
    <arm_group_label>One group of subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>Blood sample collection at different time points</description>
    <arm_group_label>One group of subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bivalent rLP2086</intervention_name>
    <description>A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.</description>
    <arm_group_label>One group of subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Stage 1:&#xD;
&#xD;
          1. Evidence of a personally signed and dated informed consent document (ICD) indicating&#xD;
             that the subject (or a legal representative) has been informed of all pertinent&#xD;
             aspects of the study.&#xD;
&#xD;
          2. Subjects who are willing and able to comply with scheduled visits, laboratory tests,&#xD;
             and other study procedures.&#xD;
&#xD;
          3. Subjects who completed a primary study and received all the scheduled injections&#xD;
             within the originally planned schedule, either with bivalent rLP2086 (either 2 or 3&#xD;
             doses) or with investigational product in cases where subject vaccine assignment is&#xD;
             blinded at the time of consent for study B1971033.&#xD;
&#xD;
          4. Subjects who completed the blood draw following the last vaccination and subjects who&#xD;
             completed the 6-month follow-up telephone call in the primary study.&#xD;
&#xD;
        Inclusion Criteria for Booster Stage Visits 7-10 (up to12 month post booster follow up):&#xD;
&#xD;
          1. Evidence of a personally signed and dated ICD indicating that the subject or subject's&#xD;
             parent(s)/legal guardian has been informed of all pertinent aspects for Visits 7 to 10&#xD;
             of the booster stage of the study.&#xD;
&#xD;
          2. Subject continues to meet all Stage 1 inclusion and none of the Stage 1 exclusion&#xD;
             criteria.&#xD;
&#xD;
          3. Subject is confirmed as having received bivalent rLP2086 in the primary vaccination&#xD;
             study.&#xD;
&#xD;
          4. Subject has completed B1971033 Stage 1 and completed the Visit 6 blood draw.&#xD;
&#xD;
          5. Subject is available for the entire period of the booster stage and the subject or&#xD;
             subject's parent(s)/legal guardian can be reached by telephone.&#xD;
&#xD;
          6. Healthy subject as determined by medical history, physical examination, and judgment&#xD;
             of the investigator.&#xD;
&#xD;
          7. Male and female subjects of childbearing potential and at risk for pregnancy must&#xD;
             agree to use a highly effective method of contraception through Visit 10 of the&#xD;
             booster stage. A subject is of childbearing potential if, in the opinion of the&#xD;
             investigator, he/she is biologically capable of having children and is sexually&#xD;
             active. Refer to Section 4.5 for further information.&#xD;
&#xD;
          8. Negative urine pregnancy test for all female subjects on the day of the booster dose.&#xD;
&#xD;
        Inclusion Criteria for Booster Stage Visit11 (26 month post booster follow up):&#xD;
&#xD;
          1. For subject participating in Visit 11, evidence of a personally signed and dated ICD&#xD;
             indicating that the subject or subject's parent(s)/legal guardian has been informed of&#xD;
             all pertinent aspects of Visit 11.&#xD;
&#xD;
          2. Subject continues to meet all Stage 1 inclusion and none of the Stage 1 exclusion&#xD;
             criteria.&#xD;
&#xD;
          3. Subject must have received 2 or 3 doses of bivalent rLP2086 in the primary study on a&#xD;
             0-, 2-, and 6-month or a 0- and 6-month schedule.&#xD;
&#xD;
          4. Subject must have completed booster vaccination at Visit 7.&#xD;
&#xD;
        Exclusion Criteria for Stage 1:&#xD;
&#xD;
          1. Subjects who are investigational site staff members directly involved in the conduct&#xD;
             of the trial and their family members, site staff members otherwise supervised by the&#xD;
             investigator, or subjects who are Pfizer employees directly involved in the conduct of&#xD;
             the trial.&#xD;
&#xD;
          2. With the exception of the primary study of bivalent rLP2086, participation in other&#xD;
             studies within the 1-month (30-day) period before study Visit 1 and/or during study&#xD;
             participation. Participation in purely observational studies is permitted.&#xD;
&#xD;
          3. Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or may&#xD;
             interfere with the interpretation of study results and, in the judgment of the&#xD;
             investigator, would make the subject inappropriate for entry into this study.&#xD;
&#xD;
          4. History of culture-proven disease caused by N meningitidis or Neisseria gonorrhoeae.&#xD;
&#xD;
          5. Bleeding diathesis or condition associated with prolonged bleeding time that would&#xD;
             contraindicate blood draw.&#xD;
&#xD;
          6. Receipt of any blood products, including gamma globulin, in the period from 6 months&#xD;
             before any study visit.&#xD;
&#xD;
          7. Vaccination with any licensed or experimental meningococcal serogroup B vaccine since&#xD;
             being enrolled in the primary Pfizer-sponsored MnB study (other than study vaccines&#xD;
             permitted in the primary study).&#xD;
&#xD;
          8. Subjects who were not compliant with primary study eligibility criteria while enrolled&#xD;
             in the primary study.&#xD;
&#xD;
        Exclusion Criteria for Booster Stage:&#xD;
&#xD;
          1. Subjects who are scheduled to receive 1 or more doses of a human papillomavirus (HPV)&#xD;
             vaccine as part of a 3-dose series during the 28 days after the booster vaccination.&#xD;
&#xD;
          2. A previous anaphylactic reaction to any vaccine or vaccine-related component.&#xD;
&#xD;
          3. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving&#xD;
             allergen immunotherapy with a licensed product and are not on stable maintenance&#xD;
             doses.&#xD;
&#xD;
          4. Bleeding diathesis or condition associated with prolonged bleeding time that would&#xD;
             contraindicate intramuscular injection.&#xD;
&#xD;
          5. A known or suspected defect of the immune system that would prevent an immune response&#xD;
             to the vaccine, such as subjects with congenital or acquired defects in B-cell&#xD;
             function, those receiving chronic systemic (oral, intravenous, or intramuscular)&#xD;
             corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the&#xD;
             United States with terminal complement deficiency are excluded from participation in&#xD;
             this study. Please refer to the study reference manual (SRM) for additional details.&#xD;
&#xD;
          6. Significant neurological disorder or history of seizure (excluding simple febrile&#xD;
             seizure).&#xD;
&#xD;
          7. Current chronic use of systemic antibiotics.&#xD;
&#xD;
          8. Current participation in another investigational study. Participation in purely&#xD;
             observational studies is acceptable.&#xD;
&#xD;
          9. Received any investigational vaccines, drugs, or devices within 28 days before&#xD;
             administration of the booster vaccination.&#xD;
&#xD;
         10. Any neuroinflammatory or autoimmune condition, including, but not limited to,&#xD;
             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.&#xD;
&#xD;
         11. Pregnant female subjects, breastfeeding female subjects, male subjects with partners&#xD;
             who are currently pregnant, or male and female subjects of childbearing potential who&#xD;
             are unwilling or unable to use a highly effective method of contraception as outlined&#xD;
             in this protocol through Visit 10 of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./ East Valley Family Physicians, PLC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Clinical Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Foundation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Health South Tampa Center for Advanced Healthcare</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Health</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Research Clinical Center</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent Medicine, PA</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics And Adolescent Medicine, P.A.</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of L Pediatrics: Downtown</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brownsboro Park Pediatrics</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research, Inc.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern Medical Clinic Lakeland Healthcare Affiliate</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center For Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc. (Prairie Fields Family Medicine, PC)</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Health Research Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Pediatric Infectious Diseases</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada,LLC</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Shelly David Senders MD Inc. dba Senders Pediatrics</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatrics, Inc</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Service (WHCRS)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BB Holdings, LLC., dba Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Inc, Jordan River Family Medicine</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088-9334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic, Inc. PS</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Clinic</name>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <zip>53566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Education Association for Clinical Health, Inc.</name>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <zip>53566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Holice</city>
        <zip>53401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50004</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>37701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Odolena Voda</city>
        <zip>25070</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Pardubice</city>
        <zip>53012</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Praha - Nusle</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Praha 6</city>
        <zip>16000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Sezemice</city>
        <zip>53304</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University hospital Skejby</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jarvenpaa Vaccine Research Clinic</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Clinic</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinder - und Jugendarzt Praxis</name>
      <address>
        <city>Bad Saulgau</city>
        <zip>88348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarzt Praxis</name>
      <address>
        <city>Bramsche</city>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infektionskliniken Malarsjukhuset</name>
      <address>
        <city>Eskilstuna</city>
        <zip>631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus</name>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <results_first_submitted>December 14, 2018</results_first_submitted>
  <results_first_submitted_qc>March 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2020</results_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01543087/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01543087/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total 698 participants enrolled in this extension study, who were enrolled in any 1 of the primary studies B1971010 (NCT01323270), B1971012 (NCT01299480), and B1971015 (NCT01461980).</recruitment_details>
      <pre_assignment_details>This study consisted of 2 stages: Stage 1 and Booster stage. Only participants from primary studies B1971010 and B1971012 who received bivalent rLP2086 in the primary study and completed Stage 1 in this study, were eligible to participate in the booster stage.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)</title>
          <description>Participants received quadrivalent meningococcal polysaccharide conjugate (MCV4) tetanus + acellular pertussis (Tdap) +Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="P4">
          <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="P5">
          <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="P6">
          <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage 1 (48 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="277"/>
                <participants group_id="P4" count="116"/>
                <participants group_id="P5" count="86"/>
                <participants group_id="P6" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="277"/>
                <participants group_id="P4" count="116"/>
                <participants group_id="P5" count="86"/>
                <participants group_id="P6" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="237"/>
                <participants group_id="P4" count="108"/>
                <participants group_id="P5" count="83"/>
                <participants group_id="P6" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer met eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Booster Stage (26 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Group1 participants (primary study B1971015)were not invited to participate in Booster stage (BS).</participants>
                <participants group_id="P2" count="60">BS was optional for eligible participants. Not all participants completing stage 1 continued to BS.</participants>
                <participants group_id="P3" count="92">BS was optional for eligible participants. Not all participants completing stage 1 continued to BS.</participants>
                <participants group_id="P4" count="64">BS was optional for eligible participants. Not all participants completing stage 1 continued to BS.</participants>
                <participants group_id="P5" count="56">BS was optional for eligible participants. Not all participants completing stage 1 continued to BS.</participants>
                <participants group_id="P6" count="32">BS was optional for eligible participants. Not all participants completing stage 1 continued to BS.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="54"/>
                <participants group_id="P6" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="54"/>
                <participants group_id="P6" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal before booster vaccination</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set included all participants enrolled in this study from primary studies B1971010, B1971012, and B1971015.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)</title>
          <description>Participants received MCV4+Tdap+Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="B4">
          <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="B5">
          <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="B6">
          <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="277"/>
            <count group_id="B4" value="116"/>
            <count group_id="B5" value="86"/>
            <count group_id="B6" value="46"/>
            <count group_id="B7" value="698"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The age of participants enrolled in B1971033 is the age of participants at Stage 1 enrollment.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.7" spread="0.7"/>
                    <measurement group_id="B2" value="15.9" spread="2.2"/>
                    <measurement group_id="B3" value="14.3" spread="2.8"/>
                    <measurement group_id="B4" value="15.8" spread="2.1"/>
                    <measurement group_id="B5" value="16.1" spread="2.4"/>
                    <measurement group_id="B6" value="15.9" spread="2.1"/>
                    <measurement group_id="B7" value="14.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="362"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="252"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="84"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="654"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="256"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="85"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 6 (Visit 1) After Primary Vaccinations</title>
        <description>For immunogenicity assessment, serum bactericidal assay using human complement (hSBA) was performed with 4 primary Neisseria meningitidis serogroup B (MnB) test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants who received bivalent rLP2086 in primary study B1971012, entered in this study at Month 12 (Visit 2). Hence, no participants enrolled from primary study B1971012 had serology results at Month 6.</description>
        <time_frame>Month 6 (Visit 1 of study B1971033)</time_frame>
        <population>Modified intent-to-treat (mITT) population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants received MCV4+Tdap+Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3c: rLP2086 (0-, 2-, and 6-Month Schedule))</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971015.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 6 (Visit 1) After Primary Vaccinations</title>
          <description>For immunogenicity assessment, serum bactericidal assay using human complement (hSBA) was performed with 4 primary Neisseria meningitidis serogroup B (MnB) test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants who received bivalent rLP2086 in primary study B1971012, entered in this study at Month 12 (Visit 2). Hence, no participants enrolled from primary study B1971012 had serology results at Month 6.</description>
          <population>Modified intent-to-treat (mITT) population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O2" value="86.5" lower_limit="71.2" upper_limit="95.5"/>
                    <measurement group_id="O3" value="83.3" lower_limit="58.6" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="0.4" upper_limit="64.1"/>
                    <measurement group_id="O2" value="72.2" lower_limit="54.8" upper_limit="85.8"/>
                    <measurement group_id="O3" value="88.9" lower_limit="65.3" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="41.0"/>
                    <measurement group_id="O2" value="36.8" lower_limit="21.8" upper_limit="54.0"/>
                    <measurement group_id="O3" value="35.3" lower_limit="14.2" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="41.0"/>
                    <measurement group_id="O2" value="64.9" lower_limit="47.5" upper_limit="79.8"/>
                    <measurement group_id="O3" value="56.3" lower_limit="29.9" upper_limit="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 12 (Visit 2) After Primary Vaccinations</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
        <time_frame>Month 12 (Visit 2 of study B1971033)</time_frame>
        <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants received MCV4+Tdap+Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 3c: rLP2086 (0-, 2-, and 6-Month Schedule))</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971015.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O7">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O8">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 12 (Visit 2) After Primary Vaccinations</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
          <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="123"/>
                <count group_id="O6" value="116"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="111"/>
                    <count group_id="O5" value="122"/>
                    <count group_id="O6" value="113"/>
                    <count group_id="O7" value="84"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="18.7" upper_limit="41.2"/>
                    <measurement group_id="O2" value="41.4" lower_limit="31.6" upper_limit="51.8"/>
                    <measurement group_id="O3" value="69.2" lower_limit="52.4" upper_limit="83.0"/>
                    <measurement group_id="O4" value="45.0" lower_limit="35.6" upper_limit="54.8"/>
                    <measurement group_id="O5" value="61.5" lower_limit="52.2" upper_limit="70.1"/>
                    <measurement group_id="O6" value="36.3" lower_limit="27.4" upper_limit="45.9"/>
                    <measurement group_id="O7" value="44.0" lower_limit="33.2" upper_limit="55.3"/>
                    <measurement group_id="O8" value="41.3" lower_limit="27.0" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="109"/>
                    <count group_id="O5" value="111"/>
                    <count group_id="O6" value="106"/>
                    <count group_id="O7" value="84"/>
                    <count group_id="O8" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="9.3" upper_limit="28.4"/>
                    <measurement group_id="O2" value="73.5" lower_limit="63.6" upper_limit="81.9"/>
                    <measurement group_id="O3" value="66.7" lower_limit="49.8" upper_limit="80.9"/>
                    <measurement group_id="O4" value="76.1" lower_limit="67.0" upper_limit="83.8"/>
                    <measurement group_id="O5" value="63.1" lower_limit="53.4" upper_limit="72.0"/>
                    <measurement group_id="O6" value="60.4" lower_limit="50.4" upper_limit="69.7"/>
                    <measurement group_id="O7" value="69.0" lower_limit="58.0" upper_limit="78.7"/>
                    <measurement group_id="O8" value="71.4" lower_limit="55.4" upper_limit="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="108"/>
                    <count group_id="O5" value="121"/>
                    <count group_id="O6" value="103"/>
                    <count group_id="O7" value="82"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O2" value="40.8" lower_limit="31.0" upper_limit="51.2"/>
                    <measurement group_id="O3" value="37.5" lower_limit="22.7" upper_limit="54.2"/>
                    <measurement group_id="O4" value="49.1" lower_limit="39.3" upper_limit="58.9"/>
                    <measurement group_id="O5" value="24.0" lower_limit="16.7" upper_limit="32.6"/>
                    <measurement group_id="O6" value="36.9" lower_limit="27.6" upper_limit="47.0"/>
                    <measurement group_id="O7" value="41.5" lower_limit="30.7" upper_limit="52.9"/>
                    <measurement group_id="O8" value="37.0" lower_limit="23.2" upper_limit="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="111"/>
                    <count group_id="O5" value="120"/>
                    <count group_id="O6" value="115"/>
                    <count group_id="O7" value="85"/>
                    <count group_id="O8" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.7"/>
                    <measurement group_id="O2" value="24.0" lower_limit="16.0" upper_limit="33.6"/>
                    <measurement group_id="O3" value="47.5" lower_limit="31.5" upper_limit="63.9"/>
                    <measurement group_id="O4" value="22.5" lower_limit="15.1" upper_limit="31.4"/>
                    <measurement group_id="O5" value="32.5" lower_limit="24.2" upper_limit="41.7"/>
                    <measurement group_id="O6" value="16.5" lower_limit="10.3" upper_limit="24.6"/>
                    <measurement group_id="O7" value="21.2" lower_limit="13.1" upper_limit="31.4"/>
                    <measurement group_id="O8" value="22.2" lower_limit="11.2" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 18 (Visit 3) After Primary Vaccinations</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
        <time_frame>Month 18 (Visit 3 of study B1971033)</time_frame>
        <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants received MCV4+Tdap+Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 3c: rLP2086 (0-, 2-, and 6-Month Schedule))</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971015.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O7">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O8">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 18 (Visit 3) After Primary Vaccinations</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
          <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="123"/>
                <count group_id="O6" value="116"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="112"/>
                    <count group_id="O5" value="117"/>
                    <count group_id="O6" value="111"/>
                    <count group_id="O7" value="85"/>
                    <count group_id="O8" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="13.9" upper_limit="34.9"/>
                    <measurement group_id="O2" value="37.1" lower_limit="27.5" upper_limit="47.5"/>
                    <measurement group_id="O3" value="57.9" lower_limit="40.8" upper_limit="73.7"/>
                    <measurement group_id="O4" value="44.6" lower_limit="35.2" upper_limit="54.3"/>
                    <measurement group_id="O5" value="51.3" lower_limit="41.9" upper_limit="60.6"/>
                    <measurement group_id="O6" value="47.7" lower_limit="38.2" upper_limit="57.4"/>
                    <measurement group_id="O7" value="47.1" lower_limit="36.1" upper_limit="58.2"/>
                    <measurement group_id="O8" value="51.1" lower_limit="35.8" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="106"/>
                    <count group_id="O5" value="114"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="83"/>
                    <count group_id="O8" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="5.3" upper_limit="22.2"/>
                    <measurement group_id="O2" value="64.9" lower_limit="54.4" upper_limit="74.5"/>
                    <measurement group_id="O3" value="56.4" lower_limit="39.6" upper_limit="72.2"/>
                    <measurement group_id="O4" value="72.6" lower_limit="63.1" upper_limit="80.9"/>
                    <measurement group_id="O5" value="53.5" lower_limit="43.9" upper_limit="62.9"/>
                    <measurement group_id="O6" value="57.8" lower_limit="47.7" upper_limit="67.6"/>
                    <measurement group_id="O7" value="62.7" lower_limit="51.3" upper_limit="73.0"/>
                    <measurement group_id="O8" value="62.8" lower_limit="46.7" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="109"/>
                    <count group_id="O5" value="113"/>
                    <count group_id="O6" value="105"/>
                    <count group_id="O7" value="81"/>
                    <count group_id="O8" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="1.6" upper_limit="14.2"/>
                    <measurement group_id="O2" value="45.8" lower_limit="35.6" upper_limit="56.3"/>
                    <measurement group_id="O3" value="39.5" lower_limit="24.0" upper_limit="56.6"/>
                    <measurement group_id="O4" value="46.8" lower_limit="37.2" upper_limit="56.6"/>
                    <measurement group_id="O5" value="23.9" lower_limit="16.4" upper_limit="32.8"/>
                    <measurement group_id="O6" value="31.4" lower_limit="22.7" upper_limit="41.2"/>
                    <measurement group_id="O7" value="39.5" lower_limit="28.8" upper_limit="51.0"/>
                    <measurement group_id="O8" value="50.0" lower_limit="34.6" upper_limit="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="110"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="113"/>
                    <count group_id="O7" value="86"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O2" value="26.5" lower_limit="18.1" upper_limit="36.4"/>
                    <measurement group_id="O3" value="31.6" lower_limit="17.5" upper_limit="48.7"/>
                    <measurement group_id="O4" value="18.2" lower_limit="11.5" upper_limit="26.7"/>
                    <measurement group_id="O5" value="29.6" lower_limit="21.4" upper_limit="38.8"/>
                    <measurement group_id="O6" value="15.9" lower_limit="9.7" upper_limit="24.0"/>
                    <measurement group_id="O7" value="24.4" lower_limit="15.8" upper_limit="34.9"/>
                    <measurement group_id="O8" value="28.3" lower_limit="16.0" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 24 (Visit 4) After Primary Vaccinations</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
        <time_frame>Month 24 (Visit 4 of study B1971033)</time_frame>
        <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants received MCV4+Tdap+Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 3c: rLP2086 (0-, 2-, and 6-Month Schedule))</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971015.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O7">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O8">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 24 (Visit 4) After Primary Vaccinations</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
          <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="123"/>
                <count group_id="O6" value="116"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="107"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="109"/>
                    <count group_id="O7" value="84"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="9.5" upper_limit="28.8"/>
                    <measurement group_id="O2" value="34.7" lower_limit="25.4" upper_limit="45.0"/>
                    <measurement group_id="O3" value="50.0" lower_limit="33.4" upper_limit="66.6"/>
                    <measurement group_id="O4" value="40.2" lower_limit="30.8" upper_limit="50.1"/>
                    <measurement group_id="O5" value="49.6" lower_limit="40.1" upper_limit="59.0"/>
                    <measurement group_id="O6" value="42.2" lower_limit="32.8" upper_limit="52.0"/>
                    <measurement group_id="O7" value="44.0" lower_limit="33.2" upper_limit="55.3"/>
                    <measurement group_id="O8" value="39.1" lower_limit="25.1" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="102"/>
                    <count group_id="O5" value="110"/>
                    <count group_id="O6" value="104"/>
                    <count group_id="O7" value="80"/>
                    <count group_id="O8" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.4" upper_limit="10.5"/>
                    <measurement group_id="O2" value="69.2" lower_limit="58.7" upper_limit="78.5"/>
                    <measurement group_id="O3" value="57.9" lower_limit="40.8" upper_limit="73.7"/>
                    <measurement group_id="O4" value="68.6" lower_limit="58.7" upper_limit="77.5"/>
                    <measurement group_id="O5" value="36.4" lower_limit="27.4" upper_limit="46.1"/>
                    <measurement group_id="O6" value="53.8" lower_limit="43.8" upper_limit="63.7"/>
                    <measurement group_id="O7" value="58.8" lower_limit="47.2" upper_limit="69.6"/>
                    <measurement group_id="O8" value="60.0" lower_limit="44.3" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="107"/>
                    <count group_id="O5" value="112"/>
                    <count group_id="O6" value="110"/>
                    <count group_id="O7" value="83"/>
                    <count group_id="O8" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="0.9" upper_limit="12.4"/>
                    <measurement group_id="O2" value="43.0" lower_limit="32.8" upper_limit="53.7"/>
                    <measurement group_id="O3" value="39.5" lower_limit="24.0" upper_limit="56.6"/>
                    <measurement group_id="O4" value="43.0" lower_limit="33.5" upper_limit="52.9"/>
                    <measurement group_id="O5" value="25.9" lower_limit="18.1" upper_limit="35.0"/>
                    <measurement group_id="O6" value="31.8" lower_limit="23.3" upper_limit="41.4"/>
                    <measurement group_id="O7" value="37.3" lower_limit="27.0" upper_limit="48.7"/>
                    <measurement group_id="O8" value="51.1" lower_limit="35.8" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="109"/>
                    <count group_id="O5" value="114"/>
                    <count group_id="O6" value="108"/>
                    <count group_id="O7" value="83"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.4" upper_limit="10.4"/>
                    <measurement group_id="O2" value="23.7" lower_limit="15.7" upper_limit="33.4"/>
                    <measurement group_id="O3" value="38.5" lower_limit="23.4" upper_limit="55.4"/>
                    <measurement group_id="O4" value="18.3" lower_limit="11.6" upper_limit="26.9"/>
                    <measurement group_id="O5" value="27.2" lower_limit="19.3" upper_limit="36.3"/>
                    <measurement group_id="O6" value="15.7" lower_limit="9.4" upper_limit="24.0"/>
                    <measurement group_id="O7" value="22.9" lower_limit="14.4" upper_limit="33.4"/>
                    <measurement group_id="O8" value="28.3" lower_limit="16.0" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 36 (Visit 5) After Primary Vaccinations</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
        <time_frame>Month 36 (Visit 5 of study B1971033)</time_frame>
        <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants received MCV4+Tdap+Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 3c: rLP2086 (0-, 2-, and 6-Month Schedule))</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971015.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O7">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O8">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 36 (Visit 5) After Primary Vaccinations</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
          <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="123"/>
                <count group_id="O6" value="116"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="102"/>
                    <count group_id="O5" value="107"/>
                    <count group_id="O6" value="108"/>
                    <count group_id="O7" value="82"/>
                    <count group_id="O8" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" lower_limit="16.7" upper_limit="40.9"/>
                    <measurement group_id="O2" value="41.7" lower_limit="31.7" upper_limit="52.2"/>
                    <measurement group_id="O3" value="60.5" lower_limit="43.4" upper_limit="76.0"/>
                    <measurement group_id="O4" value="39.2" lower_limit="29.7" upper_limit="49.4"/>
                    <measurement group_id="O5" value="49.5" lower_limit="39.7" upper_limit="59.4"/>
                    <measurement group_id="O6" value="42.6" lower_limit="33.1" upper_limit="52.5"/>
                    <measurement group_id="O7" value="42.7" lower_limit="31.8" upper_limit="54.1"/>
                    <measurement group_id="O8" value="34.1" lower_limit="20.5" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="103"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="81"/>
                    <count group_id="O8" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="1.9" upper_limit="17.0"/>
                    <measurement group_id="O2" value="58.5" lower_limit="47.9" upper_limit="68.6"/>
                    <measurement group_id="O3" value="54.1" lower_limit="36.9" upper_limit="70.5"/>
                    <measurement group_id="O4" value="67.4" lower_limit="56.8" upper_limit="76.8"/>
                    <measurement group_id="O5" value="35.0" lower_limit="25.8" upper_limit="45.0"/>
                    <measurement group_id="O6" value="58.6" lower_limit="48.2" upper_limit="68.4"/>
                    <measurement group_id="O7" value="59.3" lower_limit="47.8" upper_limit="70.1"/>
                    <measurement group_id="O8" value="50.0" lower_limit="34.2" upper_limit="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="100"/>
                    <count group_id="O5" value="103"/>
                    <count group_id="O6" value="107"/>
                    <count group_id="O7" value="81"/>
                    <count group_id="O8" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.7"/>
                    <measurement group_id="O2" value="41.9" lower_limit="31.8" upper_limit="52.6"/>
                    <measurement group_id="O3" value="38.9" lower_limit="23.1" upper_limit="56.5"/>
                    <measurement group_id="O4" value="42.0" lower_limit="32.2" upper_limit="52.3"/>
                    <measurement group_id="O5" value="30.1" lower_limit="21.5" upper_limit="39.9"/>
                    <measurement group_id="O6" value="33.6" lower_limit="24.8" upper_limit="43.4"/>
                    <measurement group_id="O7" value="48.1" lower_limit="36.9" upper_limit="59.5"/>
                    <measurement group_id="O8" value="41.9" lower_limit="27.0" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="103"/>
                    <count group_id="O6" value="109"/>
                    <count group_id="O7" value="83"/>
                    <count group_id="O8" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="21.6" lower_limit="13.9" upper_limit="31.2"/>
                    <measurement group_id="O3" value="33.3" lower_limit="19.1" upper_limit="50.2"/>
                    <measurement group_id="O4" value="16.5" lower_limit="9.9" upper_limit="25.1"/>
                    <measurement group_id="O5" value="24.3" lower_limit="16.4" upper_limit="33.7"/>
                    <measurement group_id="O6" value="20.2" lower_limit="13.1" upper_limit="28.9"/>
                    <measurement group_id="O7" value="21.7" lower_limit="13.4" upper_limit="32.1"/>
                    <measurement group_id="O8" value="18.2" lower_limit="8.2" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 48 (Visit 6) After Primary Vaccinations</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
        <time_frame>Month 48 (Visit 6 of study B1971033)</time_frame>
        <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants received MCV4+Tdap+Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 3c: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971015 received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of this study.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O7">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O8">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at Month 48 (Visit 6) After Primary Vaccinations</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).</description>
          <population>mITT population included participants who had at least 1 valid and determinate assay result in Stage 1 of Study B1971033. Here, 'Number analyzed' signifies number of participants with valid and determinate hSBA titers for the given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="123"/>
                <count group_id="O6" value="116"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="100"/>
                    <count group_id="O5" value="101"/>
                    <count group_id="O6" value="101"/>
                    <count group_id="O7" value="81"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="7.8" upper_limit="28.8"/>
                    <measurement group_id="O2" value="41.1" lower_limit="30.8" upper_limit="52.0"/>
                    <measurement group_id="O3" value="51.4" lower_limit="34.0" upper_limit="68.6"/>
                    <measurement group_id="O4" value="43.0" lower_limit="33.1" upper_limit="53.3"/>
                    <measurement group_id="O5" value="34.7" lower_limit="25.5" upper_limit="44.8"/>
                    <measurement group_id="O6" value="39.6" lower_limit="30.0" upper_limit="49.8"/>
                    <measurement group_id="O7" value="45.7" lower_limit="34.6" upper_limit="57.1"/>
                    <measurement group_id="O8" value="41.3" lower_limit="27.0" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="94"/>
                    <count group_id="O6" value="99"/>
                    <count group_id="O7" value="75"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O2" value="47.1" lower_limit="36.1" upper_limit="58.2"/>
                    <measurement group_id="O3" value="42.4" lower_limit="25.5" upper_limit="60.8"/>
                    <measurement group_id="O4" value="58.6" lower_limit="48.2" upper_limit="68.4"/>
                    <measurement group_id="O5" value="30.9" lower_limit="21.7" upper_limit="41.2"/>
                    <measurement group_id="O6" value="57.6" lower_limit="47.2" upper_limit="67.5"/>
                    <measurement group_id="O7" value="61.3" lower_limit="49.4" upper_limit="72.4"/>
                    <measurement group_id="O8" value="47.8" lower_limit="32.9" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="101"/>
                    <count group_id="O6" value="105"/>
                    <count group_id="O7" value="82"/>
                    <count group_id="O8" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="2.0" upper_limit="17.3"/>
                    <measurement group_id="O2" value="41.1" lower_limit="30.8" upper_limit="52.0"/>
                    <measurement group_id="O3" value="50.0" lower_limit="32.4" upper_limit="67.6"/>
                    <measurement group_id="O4" value="40.8" lower_limit="31.0" upper_limit="51.2"/>
                    <measurement group_id="O5" value="23.8" lower_limit="15.9" upper_limit="33.3"/>
                    <measurement group_id="O6" value="30.5" lower_limit="21.9" upper_limit="40.2"/>
                    <measurement group_id="O7" value="45.1" lower_limit="34.1" upper_limit="56.5"/>
                    <measurement group_id="O8" value="42.2" lower_limit="27.7" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="100"/>
                    <count group_id="O5" value="100"/>
                    <count group_id="O6" value="106"/>
                    <count group_id="O7" value="82"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.4" upper_limit="12.3"/>
                    <measurement group_id="O2" value="20.7" lower_limit="12.9" upper_limit="30.4"/>
                    <measurement group_id="O3" value="41.2" lower_limit="24.6" upper_limit="59.3"/>
                    <measurement group_id="O4" value="18.0" lower_limit="11.0" upper_limit="26.9"/>
                    <measurement group_id="O5" value="23.0" lower_limit="15.2" upper_limit="32.5"/>
                    <measurement group_id="O6" value="18.9" lower_limit="11.9" upper_limit="27.6"/>
                    <measurement group_id="O7" value="24.4" lower_limit="15.6" upper_limit="35.1"/>
                    <measurement group_id="O8" value="23.9" lower_limit="12.6" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Booster Stage Participants Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 1 Month After Last Vaccination in Primary Study</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
        <time_frame>1 month after last vaccination in primary study</time_frame>
        <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid,determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinate hSBA titers for given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Booster Stage Participants Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 1 Month After Last Vaccination in Primary Study</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
          <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid,determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinate hSBA titers for given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="79.2" upper_limit="96.2"/>
                    <measurement group_id="O2" value="100.0" lower_limit="88.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="91.2" lower_limit="80.7" upper_limit="97.1"/>
                    <measurement group_id="O4" value="98.4" lower_limit="91.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="77.8" lower_limit="64.4" upper_limit="88.0"/>
                    <measurement group_id="O6" value="84.4" lower_limit="67.2" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="88.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.2" lower_limit="90.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="98.4" lower_limit="91.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="93.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="96.9" lower_limit="83.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" lower_limit="77.1" upper_limit="95.1"/>
                    <measurement group_id="O2" value="93.5" lower_limit="78.6" upper_limit="99.2"/>
                    <measurement group_id="O3" value="91.4" lower_limit="81.0" upper_limit="97.1"/>
                    <measurement group_id="O4" value="85.0" lower_limit="73.4" upper_limit="92.9"/>
                    <measurement group_id="O5" value="71.2" lower_limit="56.9" upper_limit="82.9"/>
                    <measurement group_id="O6" value="79.3" lower_limit="60.3" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="74.6" upper_limit="93.9"/>
                    <measurement group_id="O2" value="96.8" lower_limit="83.3" upper_limit="99.9"/>
                    <measurement group_id="O3" value="89.5" lower_limit="78.5" upper_limit="96.0"/>
                    <measurement group_id="O4" value="81.7" lower_limit="69.6" upper_limit="90.5"/>
                    <measurement group_id="O5" value="73.1" lower_limit="59.0" upper_limit="84.4"/>
                    <measurement group_id="O6" value="87.5" lower_limit="71.0" upper_limit="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Booster Stage Participants Achieving hSBA Titer Level (&gt;=) Lower Limit of Quantitation for Each of the 4 Primary Strains Before Booster Vaccination (48 Months After Last Vaccination in Primary Study [Visit 6])</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
        <time_frame>Visit 6 of study B1971033 (48 months after last vaccination in primary study)</time_frame>
        <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid, determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinatehSBA titers for given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Booster Stage Participants Achieving hSBA Titer Level (&gt;=) Lower Limit of Quantitation for Each of the 4 Primary Strains Before Booster Vaccination (48 Months After Last Vaccination in Primary Study [Visit 6])</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
          <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid, determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinatehSBA titers for given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="35.9" upper_limit="62.5"/>
                    <measurement group_id="O2" value="48.4" lower_limit="30.2" upper_limit="66.9"/>
                    <measurement group_id="O3" value="56.1" lower_limit="42.4" upper_limit="69.3"/>
                    <measurement group_id="O4" value="55.7" lower_limit="42.4" upper_limit="68.5"/>
                    <measurement group_id="O5" value="57.4" lower_limit="43.2" upper_limit="70.8"/>
                    <measurement group_id="O6" value="48.4" lower_limit="30.2" upper_limit="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" lower_limit="29.8" upper_limit="57.7"/>
                    <measurement group_id="O2" value="41.4" lower_limit="23.5" upper_limit="61.1"/>
                    <measurement group_id="O3" value="56.4" lower_limit="42.3" upper_limit="69.7"/>
                    <measurement group_id="O4" value="43.5" lower_limit="31.0" upper_limit="56.7"/>
                    <measurement group_id="O5" value="51.9" lower_limit="37.6" upper_limit="66.0"/>
                    <measurement group_id="O6" value="43.3" lower_limit="25.5" upper_limit="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="28.1" upper_limit="54.3"/>
                    <measurement group_id="O2" value="46.7" lower_limit="28.3" upper_limit="65.7"/>
                    <measurement group_id="O3" value="49.1" lower_limit="35.6" upper_limit="62.7"/>
                    <measurement group_id="O4" value="40.3" lower_limit="28.1" upper_limit="53.6"/>
                    <measurement group_id="O5" value="46.3" lower_limit="32.6" upper_limit="60.4"/>
                    <measurement group_id="O6" value="45.2" lower_limit="27.3" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="53"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" lower_limit="24.4" upper_limit="50.7"/>
                    <measurement group_id="O2" value="33.3" lower_limit="17.3" upper_limit="52.8"/>
                    <measurement group_id="O3" value="35.1" lower_limit="22.9" upper_limit="48.9"/>
                    <measurement group_id="O4" value="12.9" lower_limit="5.7" upper_limit="23.9"/>
                    <measurement group_id="O5" value="37.7" lower_limit="24.8" upper_limit="52.1"/>
                    <measurement group_id="O6" value="34.4" lower_limit="18.6" upper_limit="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 1 Month After the Booster Vaccination (Visit 8)</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
        <time_frame>Visit 8 (1 month following the booster vaccination on Month 49)</time_frame>
        <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid, determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinatehSBA titers for given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving hSBA Titer Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 1 Month After the Booster Vaccination (Visit 8)</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
          <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid, determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinatehSBA titers for given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="53"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.8" lower_limit="83.3" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="93.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="96.7" lower_limit="88.5" upper_limit="99.6"/>
                    <measurement group_id="O5" value="98.1" lower_limit="89.9" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="89.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="88.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="93.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="98.4" lower_limit="91.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="93.0" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="89.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.8" lower_limit="83.3" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="93.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="96.8" lower_limit="88.8" upper_limit="99.6"/>
                    <measurement group_id="O5" value="94.4" lower_limit="84.6" upper_limit="98.8"/>
                    <measurement group_id="O6" value="100.0" lower_limit="89.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="53"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="88.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="93.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="93.4" lower_limit="84.1" upper_limit="98.2"/>
                    <measurement group_id="O5" value="100.0" lower_limit="93.3" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="89.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving hSBATiter Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 12 Months After the Booster Vaccination(Visit 10)</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
        <time_frame>Visit 10 (12 months following the booster vaccination on Month 60)</time_frame>
        <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid, determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinatehSBA titers for given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3a: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving hSBATiter Level Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 12 Months After the Booster Vaccination(Visit 10)</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage.</description>
          <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid, determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinatehSBA titers for given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" lower_limit="61.0" upper_limit="84.7"/>
                    <measurement group_id="O2" value="89.3" lower_limit="71.8" upper_limit="97.7"/>
                    <measurement group_id="O3" value="77.8" lower_limit="64.4" upper_limit="88.0"/>
                    <measurement group_id="O4" value="80.0" lower_limit="67.7" upper_limit="89.2"/>
                    <measurement group_id="O5" value="82.4" lower_limit="69.1" upper_limit="91.6"/>
                    <measurement group_id="O6" value="96.8" lower_limit="83.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="80.0" upper_limit="97.0"/>
                    <measurement group_id="O2" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O3" value="89.1" lower_limit="77.8" upper_limit="95.9"/>
                    <measurement group_id="O4" value="81.4" lower_limit="69.1" upper_limit="90.3"/>
                    <measurement group_id="O5" value="74.0" lower_limit="59.7" upper_limit="85.4"/>
                    <measurement group_id="O6" value="100.0" lower_limit="89.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="62"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" lower_limit="51.9" upper_limit="77.5"/>
                    <measurement group_id="O2" value="66.7" lower_limit="47.2" upper_limit="82.7"/>
                    <measurement group_id="O3" value="74.1" lower_limit="60.3" upper_limit="85.0"/>
                    <measurement group_id="O4" value="77.4" lower_limit="65.0" upper_limit="87.1"/>
                    <measurement group_id="O5" value="65.3" lower_limit="50.4" upper_limit="78.3"/>
                    <measurement group_id="O6" value="84.4" lower_limit="67.2" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="52"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="61.6" upper_limit="85.6"/>
                    <measurement group_id="O2" value="76.7" lower_limit="57.7" upper_limit="90.1"/>
                    <measurement group_id="O3" value="81.1" lower_limit="68.0" upper_limit="90.6"/>
                    <measurement group_id="O4" value="59.0" lower_limit="45.7" upper_limit="71.4"/>
                    <measurement group_id="O5" value="78.8" lower_limit="65.3" upper_limit="88.9"/>
                    <measurement group_id="O6" value="93.3" lower_limit="77.9" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving hSBA Titer Level Greater Than or Equal to(&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 26 Months After the Booster Vaccination(Visit 11)</title>
        <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage. only participants who received bivalent rLP2086 in primary study B1971010 were not analysed for this endpoint. Only participants who received bivalent rLP2086 in primary study B1971012 on a 0-, 2-, and 6-month or a 0- and 6-month vaccination schedule were eligible to be followed for 26 months after booster vaccination</description>
        <time_frame>Visit 11 (26 months following the booster vaccination on Month 74)</time_frame>
        <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid, determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinatehSBA titers for given strain.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving hSBA Titer Level Greater Than or Equal to(&gt;=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains 26 Months After the Booster Vaccination(Visit 11)</title>
          <description>For immunogenicity assessment, hSBA was performed with 4 primary MnB test strains. Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95 % CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Participants of Group 3c (participants from primary study B1971015) were not continued in booster stage. only participants who received bivalent rLP2086 in primary study B1971010 were not analysed for this endpoint. Only participants who received bivalent rLP2086 in primary study B1971012 on a 0-, 2-, and 6-month or a 0- and 6-month vaccination schedule were eligible to be followed for 26 months after booster vaccination</description>
          <population>Evaluable population:eligible participants who received scheduled investigational products, received no prohibited vaccines or treatment, had pre and post vaccination blood drawn with valid, determinate assay results and had no important protocol deviation. 'Number analyzed'=number of participants with valid,determinatehSBA titers for given strain.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 (A22)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" lower_limit="55.6" upper_limit="87.1"/>
                    <measurement group_id="O2" value="61.9" lower_limit="45.6" upper_limit="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 (A56)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="64.2" upper_limit="94.2"/>
                    <measurement group_id="O2" value="57.5" lower_limit="40.9" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 (B24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" lower_limit="61.1" upper_limit="91.0"/>
                    <measurement group_id="O2" value="59.5" lower_limit="43.3" upper_limit="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 (B44)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="48.2" upper_limit="82.0"/>
                    <measurement group_id="O2" value="62.8" lower_limit="46.7" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Local Reactions Within 7 Days After Booster Vaccination</title>
        <description>Local reactions were collected by using an e-diary and included pain at injection site, redness and swelling. Redness and swelling were graded as: none (0-2.0 centimetre [cm]), mild (2.5-5.0 cm), moderate (greater than [&gt;] 5.0-10.0 cm) and severe (&gt;10.0 cm). Pain was graded as: mild (does not interfere with activity), moderate (Interferes with activity) and severe (prevents daily activity).</description>
        <time_frame>Within 7 days after booster vaccination on Month 48</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Local Reactions Within 7 Days After Booster Vaccination</title>
          <description>Local reactions were collected by using an e-diary and included pain at injection site, redness and swelling. Redness and swelling were graded as: none (0-2.0 centimetre [cm]), mild (2.5-5.0 cm), moderate (greater than [&gt;] 5.0-10.0 cm) and severe (&gt;10.0 cm). Pain was graded as: mild (does not interfere with activity), moderate (Interferes with activity) and severe (prevents daily activity).</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" lower_limit="81.3" upper_limit="97.2"/>
                    <measurement group_id="O2" value="93.5" lower_limit="86.3" upper_limit="97.6"/>
                    <measurement group_id="O3" value="89.1" lower_limit="78.8" upper_limit="95.5"/>
                    <measurement group_id="O4" value="88.9" lower_limit="77.4" upper_limit="95.8"/>
                    <measurement group_id="O5" value="84.4" lower_limit="67.2" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="25.0" upper_limit="50.9"/>
                    <measurement group_id="O2" value="29.3" lower_limit="20.3" upper_limit="39.8"/>
                    <measurement group_id="O3" value="28.1" lower_limit="17.6" upper_limit="40.8"/>
                    <measurement group_id="O4" value="35.2" lower_limit="22.7" upper_limit="49.4"/>
                    <measurement group_id="O5" value="25.0" lower_limit="11.5" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="28.1" upper_limit="54.3"/>
                    <measurement group_id="O2" value="54.3" lower_limit="43.6" upper_limit="64.8"/>
                    <measurement group_id="O3" value="51.6" lower_limit="38.7" upper_limit="64.2"/>
                    <measurement group_id="O4" value="44.4" lower_limit="30.9" upper_limit="58.6"/>
                    <measurement group_id="O5" value="46.9" lower_limit="29.1" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="6.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="9.8" lower_limit="4.6" upper_limit="17.8"/>
                    <measurement group_id="O3" value="9.4" lower_limit="3.5" upper_limit="19.3"/>
                    <measurement group_id="O4" value="9.3" lower_limit="3.1" upper_limit="20.3"/>
                    <measurement group_id="O5" value="12.5" lower_limit="3.5" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="11.0" upper_limit="32.8"/>
                    <measurement group_id="O2" value="20.7" lower_limit="12.9" upper_limit="30.4"/>
                    <measurement group_id="O3" value="20.3" lower_limit="11.3" upper_limit="32.2"/>
                    <measurement group_id="O4" value="27.8" lower_limit="16.5" upper_limit="41.6"/>
                    <measurement group_id="O5" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="1.9" upper_limit="16.5"/>
                    <measurement group_id="O2" value="5.4" lower_limit="1.8" upper_limit="12.2"/>
                    <measurement group_id="O3" value="10.9" lower_limit="4.5" upper_limit="21.2"/>
                    <measurement group_id="O4" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O5" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="4.9" upper_limit="22.9"/>
                    <measurement group_id="O2" value="10.9" lower_limit="5.3" upper_limit="19.1"/>
                    <measurement group_id="O3" value="7.8" lower_limit="2.6" upper_limit="17.3"/>
                    <measurement group_id="O4" value="16.7" lower_limit="7.9" upper_limit="29.3"/>
                    <measurement group_id="O5" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.2" upper_limit="10.8"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.0" upper_limit="8.4"/>
                    <measurement group_id="O4" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="9.7" upper_limit="30.9"/>
                    <measurement group_id="O2" value="20.7" lower_limit="12.9" upper_limit="30.4"/>
                    <measurement group_id="O3" value="17.2" lower_limit="8.9" upper_limit="28.7"/>
                    <measurement group_id="O4" value="14.8" lower_limit="6.6" upper_limit="27.1"/>
                    <measurement group_id="O5" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="4.9" upper_limit="22.9"/>
                    <measurement group_id="O2" value="8.7" lower_limit="3.8" upper_limit="16.4"/>
                    <measurement group_id="O3" value="10.9" lower_limit="4.5" upper_limit="21.2"/>
                    <measurement group_id="O4" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O5" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="1.9" upper_limit="16.5"/>
                    <measurement group_id="O2" value="10.9" lower_limit="5.3" upper_limit="19.1"/>
                    <measurement group_id="O3" value="6.3" lower_limit="1.7" upper_limit="15.2"/>
                    <measurement group_id="O4" value="11.1" lower_limit="4.2" upper_limit="22.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Booster Vaccination</title>
        <description>Systemic reactions included: fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site and joint pain, all other systemic reactions were recorded by using an e-diary. Fever was categorized as: 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and &gt; 40.0 degree C. Vomiting was graded as: mild (1 to 2 times in 24 hours [hrs]), moderate (&gt;2 times in 24 hrs) and severe (requires intravenous [IV] hydration); Diarrhea was graded as: mild (2 to 3 loose stools in 24 hrs), moderate (4 to 5 loose stools in 24 hrs) and severe (6 or more loose stools in 24 hrs); Headache, fatigue, chills, muscle pain and joint pain was graded as: mild (does not interfere with daily activities), moderate (some interference with activity) and severe (prevents daily routine activity).</description>
        <time_frame>Within 7 days after booster vaccination on Month 48</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Booster Vaccination</title>
          <description>Systemic reactions included: fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site and joint pain, all other systemic reactions were recorded by using an e-diary. Fever was categorized as: 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and &gt; 40.0 degree C. Vomiting was graded as: mild (1 to 2 times in 24 hours [hrs]), moderate (&gt;2 times in 24 hrs) and severe (requires intravenous [IV] hydration); Diarrhea was graded as: mild (2 to 3 loose stools in 24 hrs), moderate (4 to 5 loose stools in 24 hrs) and severe (6 or more loose stools in 24 hrs); Headache, fatigue, chills, muscle pain and joint pain was graded as: mild (does not interfere with daily activities), moderate (some interference with activity) and severe (prevents daily routine activity).</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=38 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="4.7" lower_limit="1.0" upper_limit="13.1"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O5" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.0 to &lt;38.5 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.4" upper_limit="10.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 38.5 to &lt;39.0 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.0" upper_limit="8.4"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever 39.0 to 40.0 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40.0 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="3.3" lower_limit="0.7" upper_limit="9.2"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.4" upper_limit="10.8"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="3.3" lower_limit="0.7" upper_limit="9.2"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.0" upper_limit="8.4"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.0" upper_limit="8.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="3.8" upper_limit="20.8"/>
                    <measurement group_id="O2" value="13.0" lower_limit="6.9" upper_limit="21.7"/>
                    <measurement group_id="O3" value="4.7" lower_limit="1.0" upper_limit="13.1"/>
                    <measurement group_id="O4" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O5" value="18.8" lower_limit="7.2" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.8" upper_limit="18.7"/>
                    <measurement group_id="O2" value="12.0" lower_limit="6.1" upper_limit="20.4"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.4" upper_limit="10.8"/>
                    <measurement group_id="O4" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O5" value="18.8" lower_limit="7.2" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.0" upper_limit="8.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="37.5" upper_limit="64.1"/>
                    <measurement group_id="O2" value="47.8" lower_limit="37.3" upper_limit="58.5"/>
                    <measurement group_id="O3" value="56.3" lower_limit="43.3" upper_limit="68.6"/>
                    <measurement group_id="O4" value="48.1" lower_limit="34.3" upper_limit="62.2"/>
                    <measurement group_id="O5" value="37.5" lower_limit="21.1" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="19.2" upper_limit="43.9"/>
                    <measurement group_id="O2" value="28.3" lower_limit="19.4" upper_limit="38.6"/>
                    <measurement group_id="O3" value="35.9" lower_limit="24.3" upper_limit="48.9"/>
                    <measurement group_id="O4" value="22.2" lower_limit="12.0" upper_limit="35.6"/>
                    <measurement group_id="O5" value="25.0" lower_limit="11.5" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="11.0" upper_limit="32.8"/>
                    <measurement group_id="O2" value="18.5" lower_limit="11.1" upper_limit="27.9"/>
                    <measurement group_id="O3" value="20.3" lower_limit="11.3" upper_limit="32.2"/>
                    <measurement group_id="O4" value="25.9" lower_limit="15.0" upper_limit="39.7"/>
                    <measurement group_id="O5" value="12.5" lower_limit="3.5" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="49.1" upper_limit="75.0"/>
                    <measurement group_id="O2" value="60.9" lower_limit="50.1" upper_limit="70.9"/>
                    <measurement group_id="O3" value="62.5" lower_limit="49.5" upper_limit="74.3"/>
                    <measurement group_id="O4" value="51.9" lower_limit="37.8" upper_limit="65.7"/>
                    <measurement group_id="O5" value="65.6" lower_limit="46.8" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="16.4" upper_limit="40.3"/>
                    <measurement group_id="O2" value="27.2" lower_limit="18.4" upper_limit="37.4"/>
                    <measurement group_id="O3" value="35.9" lower_limit="24.3" upper_limit="48.9"/>
                    <measurement group_id="O4" value="24.1" lower_limit="13.5" upper_limit="37.6"/>
                    <measurement group_id="O5" value="31.3" lower_limit="16.1" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" lower_limit="20.6" upper_limit="45.6"/>
                    <measurement group_id="O2" value="31.5" lower_limit="22.2" upper_limit="42.0"/>
                    <measurement group_id="O3" value="23.4" lower_limit="13.8" upper_limit="35.7"/>
                    <measurement group_id="O4" value="24.1" lower_limit="13.5" upper_limit="37.6"/>
                    <measurement group_id="O5" value="31.3" lower_limit="16.1" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.7"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.3" upper_limit="7.6"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.4" upper_limit="10.8"/>
                    <measurement group_id="O4" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O5" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="13.6" upper_limit="36.6"/>
                    <measurement group_id="O2" value="31.5" lower_limit="22.2" upper_limit="42.0"/>
                    <measurement group_id="O3" value="20.3" lower_limit="11.3" upper_limit="32.2"/>
                    <measurement group_id="O4" value="18.5" lower_limit="9.3" upper_limit="31.4"/>
                    <measurement group_id="O5" value="28.1" lower_limit="13.7" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="6.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="20.7" lower_limit="12.9" upper_limit="30.4"/>
                    <measurement group_id="O3" value="12.5" lower_limit="5.6" upper_limit="23.2"/>
                    <measurement group_id="O4" value="9.3" lower_limit="3.1" upper_limit="20.3"/>
                    <measurement group_id="O5" value="18.8" lower_limit="7.2" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="3.8" upper_limit="20.8"/>
                    <measurement group_id="O2" value="9.8" lower_limit="4.6" upper_limit="17.8"/>
                    <measurement group_id="O3" value="7.8" lower_limit="2.6" upper_limit="17.3"/>
                    <measurement group_id="O4" value="7.4" lower_limit="2.1" upper_limit="17.9"/>
                    <measurement group_id="O5" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="12.3" upper_limit="34.7"/>
                    <measurement group_id="O2" value="29.3" lower_limit="20.3" upper_limit="39.8"/>
                    <measurement group_id="O3" value="18.8" lower_limit="10.1" upper_limit="30.5"/>
                    <measurement group_id="O4" value="24.1" lower_limit="13.5" upper_limit="37.6"/>
                    <measurement group_id="O5" value="15.6" lower_limit="5.3" upper_limit="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="8.4" upper_limit="29.0"/>
                    <measurement group_id="O2" value="15.2" lower_limit="8.6" upper_limit="24.2"/>
                    <measurement group_id="O3" value="7.8" lower_limit="2.6" upper_limit="17.3"/>
                    <measurement group_id="O4" value="14.8" lower_limit="6.6" upper_limit="27.1"/>
                    <measurement group_id="O5" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="13.0" lower_limit="6.9" upper_limit="21.7"/>
                    <measurement group_id="O3" value="7.8" lower_limit="2.6" upper_limit="17.3"/>
                    <measurement group_id="O4" value="5.6" lower_limit="1.2" upper_limit="15.4"/>
                    <measurement group_id="O5" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.4" upper_limit="10.8"/>
                    <measurement group_id="O4" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="4.9" upper_limit="22.9"/>
                    <measurement group_id="O2" value="16.3" lower_limit="9.4" upper_limit="25.5"/>
                    <measurement group_id="O3" value="14.1" lower_limit="6.6" upper_limit="25.0"/>
                    <measurement group_id="O4" value="18.5" lower_limit="9.3" upper_limit="31.4"/>
                    <measurement group_id="O5" value="21.9" lower_limit="9.3" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.8" upper_limit="18.7"/>
                    <measurement group_id="O2" value="9.8" lower_limit="4.6" upper_limit="17.8"/>
                    <measurement group_id="O3" value="7.8" lower_limit="2.6" upper_limit="17.3"/>
                    <measurement group_id="O4" value="7.4" lower_limit="2.1" upper_limit="17.9"/>
                    <measurement group_id="O5" value="12.5" lower_limit="3.5" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.4" upper_limit="11.7"/>
                    <measurement group_id="O2" value="6.5" lower_limit="2.4" upper_limit="13.7"/>
                    <measurement group_id="O3" value="4.7" lower_limit="1.0" upper_limit="13.1"/>
                    <measurement group_id="O4" value="9.3" lower_limit="3.1" upper_limit="20.3"/>
                    <measurement group_id="O5" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain:Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.0" upper_limit="8.4"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="3.8" upper_limit="20.8"/>
                    <measurement group_id="O2" value="14.1" lower_limit="7.7" upper_limit="23.0"/>
                    <measurement group_id="O3" value="7.8" lower_limit="2.6" upper_limit="17.3"/>
                    <measurement group_id="O4" value="13.0" lower_limit="5.4" upper_limit="24.9"/>
                    <measurement group_id="O5" value="6.3" lower_limit="0.8" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Medically Attended Adverse Event (MAE) From Booster Vaccination Phase (Visit 7 to Visit 8)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both non-serious AEs and serious adverse events (SAEs). An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
        <time_frame>From Visit 7 (Month 48) to Visit 8 (Month 49) in Booster stage</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Medically Attended Adverse Event (MAE) From Booster Vaccination Phase (Visit 7 to Visit 8)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both non-serious AEs and serious adverse events (SAEs). An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="1.9" upper_limit="16.5"/>
                    <measurement group_id="O2" value="8.7" lower_limit="3.8" upper_limit="16.4"/>
                    <measurement group_id="O3" value="12.5" lower_limit="5.6" upper_limit="23.2"/>
                    <measurement group_id="O4" value="3.7" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O5" value="12.5" lower_limit="3.5" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDCMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.2" upper_limit="10.8"/>
                    <measurement group_id="O3" value="4.7" lower_limit="1.0" upper_limit="13.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) and Medically Attended Adverse Event (MAE) From Booster Follow-Up Phase (Visit 8 to Visit 9)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
        <time_frame>Visit 8 (Month 49) to Visit 9 (Month 54) in Booster stage</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) and Medically Attended Adverse Event (MAE) From Booster Follow-Up Phase (Visit 8 to Visit 9)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An MAE was defined as a non serious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="3.9"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.4" upper_limit="10.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="17.8" upper_limit="42.1"/>
                    <measurement group_id="O2" value="12.0" lower_limit="6.1" upper_limit="20.4"/>
                    <measurement group_id="O3" value="10.9" lower_limit="4.5" upper_limit="21.2"/>
                    <measurement group_id="O4" value="11.1" lower_limit="4.2" upper_limit="22.6"/>
                    <measurement group_id="O5" value="21.9" lower_limit="9.3" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) and Medically Attended Adverse Event (MAE) From Booster Vaccination Through 6 Months After Booster Vaccination (Visit 7 to Visit 9)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An MAE was defined as a nonserious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
        <time_frame>From Visit 7 (time of booster vaccination, Month 48) to Visit 9 (6 months after booster vaccination, Month 54)</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) and Medically Attended Adverse Event (MAE) From Booster Vaccination Through 6 Months After Booster Vaccination (Visit 7 to Visit 9)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An MAE was defined as a nonserious AE (AE other than SAE) that resulted in an evaluation at a medical facility.</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (Bivalent rLP2086) and for whom safety data was available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.4" upper_limit="10.8"/>
                    <measurement group_id="O4" value="1.9" lower_limit="0.0" upper_limit="9.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" lower_limit="20.6" upper_limit="45.6"/>
                    <measurement group_id="O2" value="15.2" lower_limit="8.6" upper_limit="24.2"/>
                    <measurement group_id="O3" value="15.6" lower_limit="7.8" upper_limit="26.9"/>
                    <measurement group_id="O4" value="11.1" lower_limit="4.2" upper_limit="22.6"/>
                    <measurement group_id="O5" value="25.0" lower_limit="11.5" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Newly Diagnosed Chronic Medical Condition;(NDCMC) From the 6-Month Safety Telephone Call in the Primary Study Through 48 Months After the Last Dose in the Primary Study (Visit 6 in Stage 1)</title>
        <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC.</description>
        <time_frame>Visit 1 of B1971033 (6-month safety telephone call after last dose in primary study) to Visit 6 of B1971033 (6 months after last primary dose to 48 months after last primary dose in primary study)</time_frame>
        <population>Stage 1 safety population included all participants who had at least 1 blood draw in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1:MCV4+Tdap+Saline (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants received MCV4+Tdap+Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Newly Diagnosed Chronic Medical Condition;(NDCMC) From the 6-Month Safety Telephone Call in the Primary Study Through 48 Months After the Last Dose in the Primary Study (Visit 6 in Stage 1)</title>
          <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC.</description>
          <population>Stage 1 safety population included all participants who had at least 1 blood draw in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="277"/>
                <count group_id="O4" value="116"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="1.6" upper_limit="14.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="1.6" upper_limit="11.2"/>
                    <measurement group_id="O3" value="2.2" lower_limit="0.8" upper_limit="4.7"/>
                    <measurement group_id="O4" value="2.6" lower_limit="0.5" upper_limit="7.4"/>
                    <measurement group_id="O5" value="2.3" lower_limit="0.3" upper_limit="8.1"/>
                    <measurement group_id="O6" value="2.2" lower_limit="0.1" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Booster Vaccination Through 12 Months After Booster Vaccination (Visit 8 to Visit 10)</title>
        <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC.</description>
        <time_frame>From Visit 8 (1 month after booster vaccination, Month 49) to Visit 10 (12 months after booster vaccination, Month 60)</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Booster Vaccination Through 12 Months After Booster Vaccination (Visit 8 to Visit 10)</title>
          <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC.</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.3" upper_limit="7.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) From Booster Stage Vaccination Through 12 Months After Booster Vaccination (Visit 7 to Visit 10)</title>
        <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC.</description>
        <time_frame>From Visit 7 (time of booster vaccination, Month 48) to Visit 10 (12 months after booster vaccination, Month 60)</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) From Booster Stage Vaccination Through 12 Months After Booster Vaccination (Visit 7 to Visit 10)</title>
          <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC.</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.3" upper_limit="7.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Booster Vaccination Through 26 Months After Booster Vaccination (Visit 8 to Visit 11)</title>
        <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC. Participants who received bivalent rLP2086 in primary study B1971012 on a 0-, 2-, and 6-month or a 0- and 6-month vaccination schedule were eligible to be follow up for 26 months after booster vaccination.</description>
        <time_frame>From Visit 8 (1 month after booster vaccination, Month 49) to Visit 11 (26 months after booster vaccination, Month 74)</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From 1 Month After Booster Vaccination Through 26 Months After Booster Vaccination (Visit 8 to Visit 11)</title>
          <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC. Participants who received bivalent rLP2086 in primary study B1971012 on a 0-, 2-, and 6-month or a 0- and 6-month vaccination schedule were eligible to be follow up for 26 months after booster vaccination.</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From Booster Vaccine Through 26 Months After Booster Vaccination (Visit 7 to Visit 11)</title>
        <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC. Participants who received bivalent rLP2086 in primary study B1971012 on a 0-, 2-, and 6-month or a 0- and 6-month vaccination schedule were eligible to be follow up for 26 months after booster vaccination.</description>
        <time_frame>From Visit 7 (time of booster vaccination, Month 48) to Visit 11 (26 months after booster vaccination, Month 74)</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3b: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971012, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From Booster Vaccine Through 26 Months After Booster Vaccination (Visit 7 to Visit 11)</title>
          <description>An NDCMC was defined as a disease or medical condition, that was not identified previously and that was expected to be persistent or otherwise long-lasting in its effects. The investigator determined if the AE was an NDCMC. Participants who received bivalent rLP2086 in primary study B1971012 on a 0-, 2-, and 6-month or a 0- and 6-month vaccination schedule were eligible to be follow up for 26 months after booster vaccination.</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Booster Vaccination</title>
        <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
        <time_frame>Within 30 minutes after Booster Vaccination in Month 48</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Booster Vaccination</title>
          <description>Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Days Participants Missed Work or School Due to AE From Booster Vaccination Through 6 Months After Booster Vaccination (Visit 7 Through Visit 9)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Number of days participants missed work or school due to AE occurred following booster vaccination were reported here.</description>
        <time_frame>From Visit 7 (time of booster vaccination, Month 48) Through Visit 9 (6 months after booster vaccination, Month 54)</time_frame>
        <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available. Here, &quot;Overall number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 micrograms (mcg) of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O2">
            <title>Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: rLP2086 (0-and 6-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O4">
            <title>Group 5: rLP2086 (0- and 2-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
          <group group_id="O5">
            <title>Group 6: rLP2086 (0- and 4-Month Schedule)</title>
            <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study, and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Participants Missed Work or School Due to AE From Booster Vaccination Through 6 Months After Booster Vaccination (Visit 7 Through Visit 9)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. Number of days participants missed work or school due to AE occurred following booster vaccination were reported here.</description>
          <population>Booster stage safety population included all participants who had received the booster vaccination (bivalent rLP2086) and for whom safety data was available. Here, &quot;Overall number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="28.14"/>
                    <measurement group_id="O2" value="12.4" spread="9.72"/>
                    <measurement group_id="O3" value="10.1" spread="9.14"/>
                    <measurement group_id="O4" value="3.0" spread="2.65"/>
                    <measurement group_id="O5" value="4.8" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and Non SAEs: Visit 7 (Booster vaccination, Month 48) to Visit 11 (Month 74) [26 months]. Local reactions and systemic events: Recorded by participants in e-diary from Day 1 to Day 7 after booster vaccination in Month 48.</time_frame>
      <desc>AEs were reported only for those participants who had received the booster vaccination (bivalent rLP2086) and for whom safety information was available for disclosure. SAEs were not collected for stage 1 of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Stage1,Group 1:MCV4+Tdap+Saline (0-,2-,and 6-Month Schedule):</title>
          <description>Participants received MCV4+Tdap+Saline at Month 0, Saline only at Month 2 and 6 schedule in primary study B1971015 and were followed up for 48 months during the stage 1 of this study.</description>
        </group>
        <group group_id="E2">
          <title>Stage 1, Group 2: rLP2086 (0-, 1-, and 6-Month Schedule):</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study.</description>
        </group>
        <group group_id="E3">
          <title>Stage 1, Group 3: rLP2086 (0-, 2-, and 6-Month Schedule):</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group, and were followed up for 48 months during the stage 1 of this study.</description>
        </group>
        <group group_id="E4">
          <title>Stage 1, Group 4: rLP2086 (0-and 6-Month Schedule):</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study.</description>
        </group>
        <group group_id="E5">
          <title>Stage 1, Group 5: rLP2086 (0- and 2-Month Schedule):</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study.</description>
        </group>
        <group group_id="E6">
          <title>Stage 1,Group 6: rLP2086 (0- and 4-Month Schedule):</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and were followed up for 48 months during the stage 1 of this study.</description>
        </group>
        <group group_id="E7">
          <title>Stage 2, Group 2: rLP2086 (0-, 1-, and 6-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0-, 1-, and 6-month schedule in primary study B1971012 and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="E8">
          <title>Stage 2, Group 3: rLP2086 (0-, 2-, and 6-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0-, 2-, and 6-month schedule in primary study B1971010, B1971012 and B1971015 were included in this group. Only participants from B1971010 and B1971012 studies received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="E9">
          <title>Stage 2, Group 4: rLP2086 (0-and 6-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 6-month schedule in primary study B1971012 and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="E10">
          <title>Stage 2, Group 5: rLP2086 (0- and 2-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 2-month schedule in primary study B1971012 and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
        <group group_id="E11">
          <title>Stage 2, Group 6: rLP2086 (0- and 4-Month Schedule)</title>
          <description>Participants who received bivalent rLP2086 vaccine on 0- and 4-month schedule in primary study B1971012 and received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine at Visit 7 (approximately at Month 48) in booster stage of study B1971033.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA v 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="56" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="90" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="62" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="53" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="31" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="56" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="40" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="28" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="21" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection site erythema (redness)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection site pain (tenderness at injection site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="54" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="86" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="57" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="48" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="27" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Injection site swelling (swelling)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pyrexia (fever)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Mite allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Genitourinary chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vasoplegia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Borrelia test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vitamin K deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="27" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="44" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="36" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="26" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Orthostatic intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastrointestinal somatic symptom disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Persistent depressive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

